0001127602-24-002738.txt : 20240131 0001127602-24-002738.hdr.sgml : 20240131 20240131162350 ACCESSION NUMBER: 0001127602-24-002738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240129 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eisele Jeffrey CENTRAL INDEX KEY: 0001827326 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 24583254 MAIL ADDRESS: STREET 1: APELLIS PHARMACEUTICALS, INC. STREET 2: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-01-29 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001827326 Eisele Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Development Officer 1 Common Stock 2024-01-29 4 S 0 279 64.1382 D 58179 D Common Stock 2024-01-30 4 S 0 971 65.53 D 57208 D This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024. This is a scheduled sale from an established 10b5-1 plan. /s/ David Watson, attorney-in-fact for Jeffrey Eisele 2024-01-31